Fatal Outcomes from COVID-19 in Diabetes Patients and its Management: Impact of Diabetes and Other Comorbidities on COVID-19.

Many studies have approved that COVID-19 disease was caused by Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus-1(SARS-CoV-1), and has spread as an epidemic from across the world today. Initially, it affects the upper respiratory tract, induces viral infection in the lungs, and causes severe pneumonia in the COVID-19 infected patients. After the infection in the body, changes appear in other biomarkers in the body therby imbalancing the body response studied by the virus's pathophysiology. However, this infection starts comorbidity directly and indirectly in COVID-19 infected patients. During this period of infection, the immune system is also suppressed by the virus and initiates other diseases. The authors focus on the cardiovascular comorbidity study of COVID-19 in the current work. In the comorbidity study of COVID-19, the virus mainly affects hypertension patients. The risk factor of comorbidity of hypertension and cardiovascular disorder is 30.7%, and 11.9% with diabetes mellitus. In this study, we reveal the pathophysiology, treatment, and management of cardiovascular diseases, their risk factor, and medicine results on the COVID-19 infected patients. SARS-CoV-2 primarily targets ACE-2 receptors because this virus receives this receptor as a host for the cellular entry of the virus in the body, these shows down regulations in the maintenance of BP, and the body suffers from multi-organ failure. The other diseases related to CVS are Inflammatory cardiomyopathy, congestive heart failure, irregular heartbeat, embolism events, and Coronary infarction that also affect its pathophysiology.